Search

for
Search:

Research

5 / 1000+ results

research Medical Technologies: Pharmaceutical Cosmetology, Cosmeceuticals – Opportunities and Limitations

March 2026 in “SHILAP Revista de lepidopterología”

This review found that cosmeceuticals blend cosmetic and biological skin effects, offering promise in mild dermatoses and photoaging prevention, yet face challenges like regulatory gaps and the need for standardized definitions and pharmacovigilance systems.

Meet Our Editor: Dr. Jia-You Fang's Contributions to Drug Delivery and Nanomedicine

research Meet Our Editor

March 2017 in “Drug delivery letters”

Dr. Jia-You Fang is a highly experienced researcher in drug delivery and related fields, with numerous publications and international collaborations.

research The causes of age-related alopecia from the point of view of modern morphology

January 2025 in “JOURNAL of SIBERIAN MEDICAL SCIENCES”

This review highlights morphological factors contributing to age-related alopecia and suggests further research to understand and potentially mitigate cellular aging processes affecting hair quality.

research Microneedles as Enhancer of Drug Absorption Through the Skin and Applications in Medicine and Cosmetology

55 citations , March 2018 in “Journal of pharmacy & pharmaceutical sciences”

This article reviews the applications of microneedle technology in drug delivery, dermatology, and cosmetics, but it presents no new experimental or clinical findings.

research Advances in Nanotechnology-Based Topical Delivery Systems for Skincare Applications

January 2026 in “Pharmaceutics”

This review highlighted recent advances in nanocarrier-based topical delivery systems for skincare, emphasizing their potential to enhance ingredient stability, penetration, and targeted release while addressing specific pathophysiological skin concerns.

View more "pharmaceutical cosmetology" in research →

Community Join

5 / 1000+ results

community Pelage Pharmaceuticals Phase 3 Trials for PP405 Start in September 2026

171 upvotes 1 week ago

Pelage Pharmaceuticals is starting Phase 3 trials for PP405 in September 2026, with potential market release by 2030. Users discuss various hair loss treatments like minoxidil, finasteride, RU58841, kx, breezula, and gt20029, expressing hope for future hair restoration.

community Pelage Pharmaceutical Raises 120 million to continue PP405 Research. Link inside.

in Research/Science 73 upvotes 11 months ago

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

community Kintor Pharmaceutical’s KX-826 Shows Promising Results in Hair Loss Study

17 upvotes 1 year ago

Kintor Pharmaceutical's KX-826 shows promising results for hair loss treatment. Users discuss the use of anti-androgens like spironolactone and RU58841, noting concerns about concentration and safety.

community Cosmo Pharmaceutical (Breezula) fiscal results. Top Line Six month results expected early in the second half of this year.

25 upvotes 1 year ago

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.

community JW Pharmaceutical shows superiority of 'JW0061' in hair growth over existing treatments in US

in Research/Science 99 upvotes 2 years ago

JW0061 shows superior hair growth results compared to existing treatments, with significant increases in hair follicles. The Wnt/β-catenin pathway is crucial for hair growth, and JW0061 activates this pathway effectively.

View more "pharmaceutical cosmetology" in community →

Learn

1 / 801 results

learn KX-826

Kintor Pharmaceutical: KX-826, a New Name in Hair Loss Research KX-826 (pyrilutamide) is an experimental topical androgen receptor blocker from Kintor Pharmaceutical. It is not approved as a medicine anywhere; the company reports that its China Phase III trial met its primary endpoint at 24 weeks, but the trial data has been released through corporate announcements rather than peer-reviewed journals and long-term safety is unknown.

View more "pharmaceutical cosmetology" in learn →

Clinics

6 / 176 results

All 176 clinic results →

Experts

— no results

Try a deeper search in experts →